Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Monday that its recently approved CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that CARDAMYST, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, is now ...

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

Milestone Pharmaceuticals Inc. receives a Strong Buy rating, driven by Cardamyst's FDA approval and imminent commercial launch for PSVT. MIST's Cardamyst demonstrated rapid efficacy, favorable safety, ...

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Tuesday that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal ...